EL7.AI
StocksMedium•17 November 2026•
4 min read

FDA grants accelerated approval to Nelkarmi for advanced ALK-positive lung cancer

Key Facts

1The FDA granted accelerated approval to neladalkib on November 17, 2026, for advanced ALK-positive non-small cell lung cancer after specified treatments.
2The response rate was 49% after alectinib, compared with 32% in the group previously treated with multiple therapies and platinum-based chemotherapy.
3The ALKOVE-1 trial included two groups of 67 and 155 patients, based on their prior treatments.
4The recommended dose is 150 mg by mouth once daily.

The U.S. Food and Drug Administration (FDA) on November 17, 2026, granted accelerated approval to neladalkib, marketed as Nelkarmi, to treat adults with locally advanced or metastatic ALK-positive non-small cell lung cancer after specified prior treatment. The agency named Nuvalent in its approval announcement, while GSK is linked to the drug following its acquisition of Nuvalent in July 2026. The approved use is limited to patients who have met one of two prior-treatment pathways, according to the FDA announcement. This places the drug among treatment options for a defined group of patients whose disease has progressed after ALK-targeted therapies. The approval followed an assessment of data from the ALKOVE-1 trial, which included two groups based on the treatments patients had received before using the drug.

The first pathway covers patients who had previously received one ALK tyrosine kinase inhibitor, which must have been alectinib. The second covers patients who had received two or more prior ALK inhibitors, along with platinum-based chemotherapy. These criteria place the approval at a later stage of treatment, rather than extending it to all people with lung cancer or all patients with ALK-positive disease. In ALKOVE-1, one group comprised 67 patients previously treated with alectinib, and another comprised 155 patients who had received two or more inhibitors along with platinum-based chemotherapy. The trial was multicenter, single-arm, open-label and multi-cohort, according to the FDA.

The confirmed objective response rate was 49% in the group of patients previously treated with alectinib. Among responders in this group, responses lasted at least six months in 76% and at least 12 months in 52%. In the group that had received two or more prior ALK inhibitors and platinum-based chemotherapy, the objective response rate was 32%. Responses lasted at least six months in 69% of responders in this group, and at least 12 months in 51%. These results show differences in response rates and duration between the two groups defined by prior treatments, as reported in FDA data on ALKOVE-1.

The pivotal data were preceded by an analysis announced in November 2025 that included 253 patients previously treated with ALK inhibitors. The median number of prior lines of treatment in the analysis group was three, and 51% of patients had received prior chemotherapy. In preliminary trial data published in 2025, the intracranial response rate was 32% among patients with measurable brain lesions. The rate reached 63% among patients who had not previously received lorlatinib. These figures relate to data published in 2025 and provide background on the study group and its preliminary results; they are not new results announced with the November 17, 2026, approval.

On the asset’s ownership, GSK announced an agreement in June 2026 to acquire Nuvalent for $10.6 billion, with neladalkib one of the two lung cancer inhibitors covered by the agreement. The acquisition was completed on July 15, 2026, according to information in the approval record. The FDA therefore attributed the approval to Nuvalent in its announcement, while the drug is part of the company acquired by GSK. The agency also granted the application priority review, and neladalkib had received breakthrough therapy and orphan drug designations. These designations and the deal context provide regulatory and corporate background to the approval, without changing the defined group of patients covered by the use.

The drug label’s warnings include liver, kidney and eye toxicity, elevated creatine phosphokinase, and embryo-fetal toxicity. The most common adverse reactions, defined as occurring in 20% or more of patients, include liver toxicity, musculoskeletal pain, constipation, taste disturbance, peripheral neuropathy, edema and fatigue. The FDA recommends a dose of 150 mg by mouth once daily, with or without food. Treatment continues until disease progression or unacceptable toxicity. These conditions set out the dosage and duration of use as stated in the agency’s recommendation, alongside the warnings listed in the label.

Open on chart